Progress of chimeric antigen receptor T-cell in treatment of lymphoma
10.3760/cma.j.cn115356-20220102-00002
- VernacularTitle:嵌合抗原受体T细胞治疗淋巴瘤研究进展
- Author:
Zhitao YING
1
;
Jun ZHU
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Lymphoma;
Chimeric antigen receptor T cell;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2022;31(3):129-132
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) has changed the treatment landscape of lymphoma. Plenty of research progresses have been made at 63rd annual meeting of American Society of Hematology. Studies with long-term follow-up indicated that CD19 CAR-T is expected to cure 30%-40% of relapsed or refractory large B-cell lymphoma (LBCL). A few studies indicated that CD19 CAR-T would be applied in the second-line or first-line therapy for LBCL. Real world studies further confirmed the efficacy and safety of CD19 CAR-T in treatment of relapsed or refractory follicular lymphoma and mantle cell lymphoma. CAR-T therapy has a promising prospect in the cinical application.
